Sina Nikayin

Abstract Genome-wide association studies (GWASs) of major depressive disorder (MDD) have recently achieved extremely large sample sizes and yielded substantial numbers of genome-wide significant loci. Because of the approach to ascertainment and assessment in many of these studies, some of these loci appear to be associated with dysphoria rather than with MDD, potentially decreasing the clinical relevance of the findings.

Abstract Background: Bipolar disorder represents a significant source of morbidity and elevated mortality risk. Ketamine has emerged as a powerful antidepressant; however, there have been few trials of ketamine in bipolar depression and no trials with esketamine in bipolar depression, and few data exist from real-world settings. Here, we report outcomes from a cohort of patients with bipolar depression treated with ketamine/ esketamine in a real-world setting.

The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents Expectations affect the course of many medical conditions, impacting key measures, including long-term mortality1 and surgical outcomes.2 Expectations account for a substantial proportion of the overall therapeutic effect of some pharmacological treatments; for example, up to 50% of the effectiveness of pain therapeutics may be expectation driven.3 Expectations can also be tempered by previous...